We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

By LabMedica International staff writers
Posted on 24 Nov 2021
Print article
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)
Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated cellular blood components.

HTLV-associated syndromes are considered as neglected diseases for which there are no vaccines or therapies available, making it particularly important to ensure the best possible diagnosis to enable proper counseling of infected persons and avoid secondary transmission. The virus can cause adult T-cell leukemia/lymphoma (ATL) and progressive nervous system condition known as HTLV-1-associated myelopathy or tropical spastic paraparesis.

A large team of scientists from the commercial company InfYnity Biomarkers (Lyon, France) collaborated with several academic institutions to develop and validate a new high-performance multiplex immunoassay for confirmation and discrimination of HTLV-1 and HTLV-2 strains. The team conducted a prospective study with samples from the USA-based cohort HTLV Outcomes Study (HOST) which includes samples from subjects recruited from five major US blood donation centers and 694 frozen serum specimens were obtained from the cohort repository. Included in the study was only the first sample tested of each participant, more specifically, 199 HTLV-positive samples from 199 participants (100 HTLV-1 from 100 patients and 99 HTLV-2 from 99 patients) and 198 negative samples from 198 participants. Other samples were collected from France and Canada.

The multiplex platform was used first as a tool to identify suitable antigens and in a second step for assay development. The Multi-HTLV assay is composed of (i) three confirmatory antigen spots for binding specific HTLV-1 and HTLV-2 antibodies and derived from common-type and type-specific immunodominant epitopes of env GP21, env GP46 and gag P19; and (ii) three discriminatory antigen spots derived from type-specific immunodominant epitopes of HTLV-1 env GP46, HTLV-1 gag P19 and HTLV-2 env GP46.

The Multi-HTLV test was performed very similarly to a standard ELISA assay enabling simultaneous detection of circulating antibodies to a set of selective and validated antigens. Each plate was read and analyzed both visually and using a specific microarray reader sciREADER CL2 (SCIENION, Berlin, Germany) which acquires high-resolution digital images and an integrated software calculates the pixel intensity for each spot.

The investigators reported that the Multi-HTLV assay demonstrated very high performance for confirmation and strain discrimination with 100% sensitivity, 98.1% specificity and 100% of typing accuracy in validation samples. The assay can be interpreted either visually or automatically with a colorimetric image reader and custom algorithm, providing highly reliable results. They observed in 35 of 60 patients a certain dynamic in antibody levels between the initial donation and 10–11 years of follow-up.

The authors concluded that the newly developed Multi-HTLV is very competitive with currently used confirmatory assays and reduces considerably the number of indeterminate results. The multiparametric nature of the assay opens new avenues to study specific serological signatures of each patient, follow the evolution of infection, and explore utility for HTLV disease prognosis. The study was published on November 1, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
InfYnity Biomarkers
SCIENION


Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
New
Undercounter Laboratory Refrigerator
iLR105-GX
New
Cytology Sample Processor
SDSCP9000 CytoPath Processor
New
Silver Supplier
COVID-19 Ag Self Test
OnSite COVID-19 Ag Self Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more

Immunology

view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more

Pathology

view channel
Illustration

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more

Technology

view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more

Industry

view channel
Illustration

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.